LifeMD (NASDAQ:LFMD) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Key Points

• LifeMD reported Q1 EPS of ($0.20), missing consensus by $0.06, while revenue of $50.16M topped estimates; the quarter included a GAAP net loss of $9.6M and an adjusted EBITDA loss of about $4.5M.
• The company added more than 42,000 net telehealth subscribers (ending with >365,000), saw strong traction in weight‑management and women's‑health programs, and reaffirmed 2026 guidance of $220–$230M with a path to >$250M revenue and >$25M adjusted EBITDA run‑rate by Q4.
• Operationally gross margin expanded ~420 bps to 88% from in‑house pharmacy and lower fulfillment costs and the firm is scaling via AI and a 50‑state pharmacy, but shifting product mix to branded GLP‑1s, limited partner details and a modest Q2 guide of $47–$50M (adj. EBITDA -$2M to $1M) pose execution risks.

LifeMD (NASDAQ:LFMD - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06), Zacks reports. LifeMD had a net margin of 6.58% and a negative return on equity of 83.93%. The firm had revenue of $50.16 million for the quarter, compared to analyst estimates of $48.84 million.

Here are the key takeaways from LifeMD's conference call:

• Q1 revenue of $50.2 million beat guidance and the company added >42,000 net telehealth subscribers (its largest quarter), ending with >365,000 subscribers; management reaffirmed 2026 guidance of $220–$230M and a path to >$250M revenue and >$25M adjusted EBITDA run‑rate by Q4.
• Rapid traction in core care areas — weight management sign‑ups rose ~120% sequentially to nearly 100,000 patients with improved CACs, and the women's health program grew >7x from the Q4 base with on‑therapy retention north of 80%.
• Gross margin expanded ~420 bps to 88% driven by in‑house pharmacy and lower fulfillment costs, but Q1 showed a GAAP net loss of $9.6M and an adjusted EBITDA loss of ~$4.5M due to front‑loaded marketing that management expects will normalize and improve profitability in H2.
• Scaling levers — aggressive AI deployment to increase provider capacity, a 22,500 sq ft, 50‑state pharmacy processing ~20,000 prescriptions/month, and insurance coverage rolling from ~112M toward ~230M covered lives (including a Medicare GLP‑1 Bridge launching July 1) — are positioned to support retention and margin expansion.
• Strategic and execution risks remain as the product mix shifts from compounded to branded GLP‑1s (pressuring YoY revenue and producing variable unit economics), details on Novo/Lilly partnerships are limited under NDA, and Q2 guide is modest at $47–$50M revenue and adjusted EBITDA of -$2M to $1M.

LifeMD Price Performance

Shares of LifeMD stock traded up $0.14 during trading hours on Wednesday, hitting $5.27. The company's stock had a trading volume of 1,446,195 shares, compared to its average volume of 1,171,613. LifeMD has a 12 month low of $2.56 and a 12 month high of $15.84. The stock has a 50 day moving average of $3.79 and a 200 day moving average of $3.95. The company has a market capitalization of $250.85 million, a PE ratio of 20.27 and a beta of 2.03.

Institutional Investors Weigh In On LifeMD

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of LifeMD by 6.7% during the third quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company's stock worth $15,120,000 after buying an additional 140,749 shares during the period. Federated Hermes Inc. boosted its position in shares of LifeMD by 278.1% during the fourth quarter. Federated Hermes Inc. now owns 980,285 shares of the company's stock worth $3,343,000 after buying an additional 721,018 shares during the period. Geode Capital Management LLC boosted its position in shares of LifeMD by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 959,700 shares of the company's stock worth $3,273,000 after buying an additional 11,324 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of LifeMD by 1,767.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company's stock worth $5,924,000 after buying an additional 411,651 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of LifeMD by 581.2% during the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company's stock worth $5,619,000 after buying an additional 352,004 shares during the period. 35.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on LFMD shares. Loop Capital set a $10.00 price objective on LifeMD in a report on Thursday, March 12th. Weiss Ratings reiterated a "sell (e+)" rating on shares of LifeMD in a report on Friday, March 27th. Mizuho upgraded LifeMD from a "neutral" rating to an "outperform" rating and upped their price objective for the company from $6.00 to $8.00 in a report on Monday, March 16th. BTIG Research reiterated a "buy" rating and issued a $10.00 price objective on shares of LifeMD in a report on Monday. Finally, Wall Street Zen upgraded LifeMD from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $9.14.

About LifeMD

LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.